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Abstract
Expression of alternatively spliced mRNA variants at specific stages of development or in specific cells and tissues contributes to the
functional diversity of the human genome. Aberrations in alternative splicing were found as a cause or a contributing factor to the
development, progression, or maintenance of various diseases including cancer. The use of antisense oligonucleotides to modify aberrant
expression patterns of alternatively spliced mRNAs is a novel means of potentially controlling such diseases. However, to utilize antisense
oligonucleotides as molecular chemotherapeutic agents, the global effects of these molecules need to be examined. The advent of gene
expression array technology has now made it possible to simultaneously examine changes that occur in the expression levels of several
thousand genes in response to antisense treatment. This analysis should help in the development of more specific and efficacious antisense
oligonucleotides as molecular therapeutics. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Conservative estimates suggest that over 35% of all pre-
mRNAs are spliced to yield alternative variants, the trans-
lated products of which may have very different functions.
An unexpectedly small number of human genes contrasted
with the complexity of the expressed gene products suggests
that alternative splicing may be even more frequent. This
review will present examples of the association between
deregulation of the process of alternative splicing and
genetic diseases and cancer. In addition, the potential use
of antisense oligonucleotides to modify splicing pathways
as a molecular chemotherapy will be discussed.
2. Aberrant splicing associated with disease
How the cell decides which alternative splice site to
utilize is not fully understood. However, it is generally
believed that splice site selection is determined by competi-
tion between splicing sequence elements for splicing factors
during spliceosome assembly. See recent reviews for more
detailed descriptions [1–4]. Aberrant splicing can result in
deleterious consequences for the organism. In fact, approx-
imately 15% of all mutations that cause genetic diseases
result in defective splicing of pre-mRNA [5]. For example,
aberrant pre-mRNA splicing occurs in genetic diseases such
as h-thalassemia [6], cystic fibrosis [7], neurofibromatosis
type 1 [8], ataxia-telangiectasia [9], and congenital lipoid
adrenal hyperplasia [10]. Aberrant splicing events are also
associated with neurological disorders [11] such as splicing
of the IKBKAP pre-mRNA in familial dysautonomia [12].
Deregulated alternative splicing also results in the inap-
propriate expression levels of correct splice variants, which
leads to altered cellular processes. A variety of cancers
express an altered ratio of specific splice variants, suggesting
that splice site selection is aberrantly regulated in cancer
cells. For recent reviews, the reader is referred to Refs.
[13,14]. Table 1 gives examples of some alternatively spliced
pre-mRNAs and several cancers that are associated with
specific splice variants. Many cancer-related alternatively
spliced genes are associated with control of cellular signal-
ing, proliferation, cell cycle, apoptosis, and DNA double-
strand break repair. While the exact functions of many of the
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cancer-related alternative splice variants are unknown, it
seems likely that the shift in splicing results in variants that
impart an increased survival capability on the cell. It there-
fore seems that manipulating the splicing pattern of those
pre-mRNAs can be effective as a means to control a variety
of diseases, including cancer.
3. Control of splice site selection by antisense
oligonucleotides
To control pre-mRNA splicing patterns, antisense oligo-
nucleotides must hybridize with specific splice sites and
block spliceosome formation at the targeted splice site. This,
because of the flexibility of splicing machinery, does not
result in total inhibition of splicing, but in a shift of the
spliceosome to another splice site. As a consequence, an
alternative splicing pattern is established or a normally used
alternative splice site is used with increased efficiency. It has
been shown in this and other laboratories that antisense
oligonucleotides modify the splicing patterns of pre-mRNAs
that harbor aberrant splice sites or aberrant sequence elements
involved in splicing. For example, antisense oligonucleotides
have been used to restore correct pre-mRNA splicing patterns
of h-globin in h-thalassemia [15–21] and cystic fibrosis
transmembrane receptor (CFTR) in cystic fibrosis [22].
Antisense oligonucleotides have also been used to induce
an alternative splicing pattern in a dystrophin pre-mRNA in
Duchenne’s muscular dystrophy [23,24] and affect the level
of expression of Bcl-x splice variants in cancer cells [25,26].
In order to use antisense oligonucleotides to shift splicing
patterns, the oligonucleotides must be stable in serum,
produce high Tm and RNase H resistant oligonucleotide-
RNA duplexes, and have the ability to enter the nucleus (the
site of pre-mRNA splicing). This is accomplished by
modification of the chemistries of oligonucleotide sugars,
internucleotide linkages, and nucleotide bases. Examples
include substitution of the 2V-hydroxyl with O-methyl, O-
methoxyethyl, and O-aminopropyl residues or derivatives
such as morpholino, N3V!P5V phosphoroamidate, peptide
nucleic acids, and methylphosphonate molecules. For a
more detailed review, see Ref. [13]. In order to deliver the
oligonucleotides to the nucleus, oligonucleotides have con-
ventionally been complexed with cationic lipids. However,
more recently, it has been found that several of the modified
oligonucleotides have the ability to enter the nucleus with-
out the aid of cationic lipids [17].
4. Modification of splicing in cancer-related pre-mRNAs
Many cancer-related pre-mRNAs that undergo alterna-
tive splicing are associated with apoptosis. Frequently, their
splice variants have opposing functions in either promoting
or preventing apoptosis. For reviews, see Refs. [13,14,27].
Thus, it appears that altered splicing patterns of many pre-
mRNAs in neoplastic cells may impart an augmented
capability of cellular survival. It then follows that modifi-
cation of these splicing patterns may inhibit cancer cell
growth and provide anticancer treatments. An antisense
oligonucleotide-induced shift in splicing may be particularly
effective because in this approach, lowering the level of an
anti-apoptotic splice variant should simultaneously increase
the levels of its pro-apoptotic counterpart. Recent results
illustrating the effects of modification of splicing of a
cancer-related gene, Bcl-x, are described below.
Bcl-x is an alternatively spliced member of the Bcl-2
family of apoptotic proteins. Use of the downstream alter-
native 5Vsplice site within exon 2 results in Bcl-xL mRNA;
the translated Bcl-xL protein has anti-apoptotic functions.
Use of the upstream alternative 5Vsplice site within exon 2
results in Bcl-xS protein, which promotes apoptosis. These
two proteins appear to play critical roles during proper
development. For example, Bcl-xL may contribute to the
long-term survival of mature neural structures, while Bcl-xS
may be important for the higher turnover rates of immature
thymocytes undergoing selection [28]. In addition to con-
tributing to the normal development of an organism, Bcl-xL
is overexpressed in a number of human cancers such as
multiple myeloma [29], small cell lung cancer [30], and
breast cancer [31] and may render cells resistant to chemo-
therapeutics [32,33]. On the other hand, Bcl-xS inhibits pro-
survival functions of Bcl-xL and Bcl-2 [28]. Two recent
Table 1
Alternatively spliced pre-mRNAs and examples of some cancers harboring
specific splice variants
pre-mRNA Example of cancers harboring
specific variants (refs.)
Proliferation/ FGFR1 glioblastoma [55–57]
signaling FGFR2 prostate [58–60]
FGFR3 colorectal [61]
FGFR4 gastric, colon, pancreatic [62]
CD44 various [63–66]
BDNF neuroblastomas [67]
HER2 various, including gastric [68], breast [69]
Trx-1 various [70]
PTPN6 acute myeloid leukemia [71]
Cell cycle/
apoptosis
Bcl-x various, including prostate [72],
ovarian [73], leukemia [74]
Bax various [75], including breast [76–78]
FHIT various [79], including renal cell [80],
lung [81]
p73 neuroblastomas [82], ovarian [83],
breast [84]
mdm2 astrocytoma [85], ovarian, bladder [86],
breast [87]
WT1 Wilms’ tumor and leukemias [88–90]
DNA excision/ BRCA1 breast, ovarian [91]
repair BRCA2 breast [92]
XPG lung [93,94]
The pre-mRNAs are organized according to cellular function. Listed to the
right of the pre-mRNA are some types of cancers that specific splice
variants of the pre-mRNAs have been detected in (either in cell lines or in
tissues from cancer patients).
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papers report the use of antisense oligonucleotides in
modification of splicing of Bcl-x pre-mRNA (Fig. 1A)
[25,26].
Taylor et al. [25] targeted a 2V-O-methoxyethyl phosphor-
othioate oligoribonucleotide to a sequence adjacent to the
alternative 5Vsplice site of Bcl-xL pre-mRNA expressed in a
human lung cancer epithelial cell line, A549. Transfection
of the cells with the oligonucleotide in a complex with a
cationic lipid delivery agent resulted in an increase of the
pro-apoptotic Bcl-xS and a decrease in the anti-apoptotic
Bcl-xL splice variants. However, in spite of the changed
ratio of pro- and anti-apoptotic proteins, the treatment did
not induce apoptosis in the cells. The increase in Bcl-xS and
decrease in Bcl-xL did sensitize the cells to two different
apoptosis inducers, cisplatin, and irradiation.
We have reported the use of 2V-O-methyl phosphoro-
thioate oligonucleotide (5VBcl-x AS) targeted to the alter-
native 5Vsplice site of Bcl-xL in prostate (PC3) and breast
(MCF7) cancer cell lines [26]. The shift in splicing (Fig. 1B)
resulted in a marked decrease in cell viability and increased
apoptosis in both cell lines as determined by colony for-
mation and poly-ADP-ribose polymerase (PARP) assays.
Interestingly, the extent and time course of induction of
apoptosis, as determined by PARP cleavage, was lower and
slower in the MCF7 compared with PC3 cells (Fig. 2A). In
addition, the extent of overall cell death, as determined by
colony formation, was lower in MCF7 cells than in PC3
cells (Fig. 2B).
The differences observed in the cellular responses to
5VBcl-x AS treatment were also seen in their sensitization to
chemotherapeutic agents. 5VBcl-x AS treatment was less
effective in sensitizing MCF7 cells to various chemother-
apeutic agents than it was in PC3 cells. For example, PC3
cells treated with 5VBcl-x AS were approximately three
times more sensitive to 5-fluorouracil than cells treated with
a negative control, randomized oligonucleotide. The same
treatment of MCF7 cells resulted in 1.5 fold sensitization. A
similar relationship held true for the sensitization of PC3
and MCF7 cells to several other chemotherapeutic reagents
(Mercatante and Kole, unpublished data).
The above results show that altering splicing patterns has
different effects depending upon the cellular milieu. We
hypothesized that Bcl-2 could be a likely candidate to mod-
ulate cellular responses to 5VBcl-x AS. This anti-apoptotic
gene is up-regulated in many cancers and provides resistance
to various chemotherapeutic agents. Furthermore, it is highly
expressed in MCF7 cells. However, culturing MCF7 cells in
media with charcoal stripped serum to downregulate Bcl-2 to
Fig. 1. Bcl-x pre-mRNA is alternatively spliced to yield two products with
opposing functions. (A) Alternative splicing pathways for Bcl-xL (anti-
apoptotic) and Bcl-xS (pro-apoptotic). Dashed line, Bcl-xS alternative
splicing pathway; dotted line, Bcl-xL alternative splicing pathway; boxes,
exons; line, introns; short bar below 5Vsplice site, antisense oligonucleotide
designed to shift the splicing pathway from Bcl-xL to Bcl-xS. (B) RT-PCR
results. RNA isolated from PC3 cells transfected with 5VBcl-x AS exhibited
a dose dependent shift in splicing from Bcl-xL to Bcl-xS. RNA isolated
from PC3 cells treated with random oligonucleotide (negative control) did
not show this shift in splicing (figure was modified from Ref. [26]).
Fig. 2. Shifting splicing from Bcl-xL to Bcl-xS induced apoptosis. PC3 and
MCF7 cells were transfected with 5VBcl-x AS at concentrations that yielded
approximately 55% shift in splicing (0.08 AM for PC3 and 0.4 AM for
MCF7). (A) Examination of the amount of PARP cleaved (an indicator of
apoptosis) showed that 5VBcl-x AS induced apoptosis faster and to a greater
extent in PC3 cells than in MCF7 cells (figure was modified from Ref. [26])
(B) Treatment with 5VBcl-x AS also decreased cell viability (measured by
colony formation as a percentage of mock treated cells) to a greater extent
in PC3 cells versus MCF7 cells.
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levels below those in PC3 cells did not increase apoptosis and/
or cell death of 5VBcl-x AS treated MCF7 cells [26]. Similar
analysis of several other genes suggested that the endogenous
levels of Bcl-x itself may be amore significant indicator of the
effectiveness of 5VBcl-x AS on inducing apoptosis (Merca-
tante and Kole, unpublished data).
The above analysis was limited to a several probable
candidates and was carried out with one gene at the time.
Recent developments in gene array technology allow simul-
taneous analysis of vast numbers of genes and identification
of the important ones, which may have not been predicted
by the existing data. For example, Cho et al. [34] found that
antisense oligonucleotides designed to affect one gene also
affected the expression of several other genes. Targeting
these genes may enhance the biological effects of the
original treatment and provide new insights into the devel-
opment of combinations of antisense chemotherapeutics
based on the molecular actions of the drugs. Furthermore,
it may be possible to determine whether the antisense
oligonucleotide treatment is clinically appropriate (i.e., does
the treatment alter other genes in a way that enhances the
desired effect while minimizing unwanted side effects).
5. Gene expression changes in response to antisense
treatment
In the field of cancer research, gene arrays have been
recently used to gain insight to the molecular basis of the
disease [35,36]. Examples of this include determination of
genetic changes associated with the progression of cancer
[37,38] and with under- or over-expression of key proteins
in cancer cells [39–41]. Identification of key genes that are
up-regulated in more advanced cancers may indicate good
targets for downregulation by antisense oligonucleotides.
Gene expression array-based analyses have also identified
changes that occur in response to various cancer treatments
[42] and those responsible for resistance to therapeutics
[43–45]. The data from experiments such as these may be
used to tailor specific treatments to individuals that exhibit
certain expression profiles.
Microarray analysis of gene expression showed that anti-
sense oligonucleotides targeted to the RIa subunit of PKA
not only induced downregulation of the targeted mRNA, but
also induced changes in various other genes [34]. These
changes were similar in two different cell lines, indicating
that the treatment affected similar genomic pathways. This
was expected since RIa antisense treatment in various other
cancer cells resulted in similar anti-proliferative effects [46].
Since PC3 and MCF7 cells responded to 5VBcl-x AS 2V-O-
methyl phosphorothioate oligonucleotide treatment differ-
ently [26], we have recently carried out cDNA microarray
experiments to examine gene expression patterns induced in
both cell lines in response to the treatment.
PC3 and MCF7 cells were transfected with 5VBcl-x AS,
complexed with transfection reagent, at concentrations that
yielded approximately 55% shift in splicing from Bcl-xL to
Bcl-xS, (i.e. 0.08 AM for PC3 and 0.4 AM for MCF7). As a
negative control, cells were treated in parallel with the same
respective concentrations of random oligonucleotides (see
Ref. [26] for a more detailed description of the treatment).
At 36 h post transfection, total RNA was isolated from
5VBcl-x AS and random oligonucleotide treated cells then
labeled with Cy3 or Cy5, respectively. The labeled probes
were co-hybridized to gene microarrays containing approx-
imately 10,000 cDNAs fixed to a glass slide (University of
North Carolina at Chapel Hill Genomics Core Facility). The
Fig. 3. Expression profiles of genes in MCF7 and PC3 cells treated with
5VBcl-x AS. Cells were treated with 5VBcl-x AS at concentrations that
yielded approximately 55% shift in splicing (0.08 AM for PC3 and 0.4 AM
for MCF7) or random oligonucleotide (0.08 AM for PC3 and 0.4 AM for
MCF7). RNAwas isolated 36 h post transfection, labeled with Cy3 or Cy5
dyes, and hybridized to human cDNA microarrays harboring approximately
10,000 cDNAs (both random oligonucleotide and 5VBcl-x AS treated RNA
from the same cell line were hybridized together). After sorting through the
resulting data to discard any poor quality spots using Gene Pix Pro
software, the intensity of the Cy3 (5VBcl-x AS treated cells) and Cy5
(random oligonucleotide treated cells) signals were plotted against each
other for each cDNA spot (approximately 7000 cDNAs are plotted for each
cell line). Scatter plots show that the expression profiles are different for
PC3 (A) and MCF7 (B) 5VBcl-x AS treated cells.
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analysis indicated that expression levels of approximately
308 genes in PC3 cells and 518 in MCF7 cells were altered
more than 2.5-fold in antisense treated versus random
oligonucleotide treated cells. Scatter plots of the results
(Fig. 3) indicate that gene up-regulation was more pro-
nounced in MCF7 cells. The significance of this observation
is as yet not clear.
While it appears that many genes were differentially
regulated in the two cell lines, we identified several genes
that displayed similar expression patterns. For example,
cDNA microarray analysis showed that the apoptosis-related
genesMcl-1, Bak, and Bax remained unaltered in response to
5VBcl-x AS treatment in both MCF7 and PC3 cells. This is in
agreement with the results obtained by RNAse protection
assays that showed no significant changes in expression of
these mRNAs in response to 5VBcl-x AS in either cell line
(Mercatante and Kole, unpublished data).
Further examination of genes with altered expression
levels in response to 5VBcl-x AS treatment showed changes
specific to each cell line. The list of a few selected genes
(Table 2) indicates that they are involved in apoptosis, cell
signaling, nucleic acid and protein synthesis, cell structure,
and ion transport. One gene, Daxx (death associated protein
6), which codes for a protein with pro-apoptotic functions
and transcriptional repressor functions [47–50], was upre-
gulated in PC3 cells but downregulated in MCF7 cells. It is
possible that upregulation of Daxx in PC3 cells stimulates
pro-death pathways that lead to a more rapid and effective
means of 5VBcl-x AS-induced apoptosis. Another candidate
gene, c-met proto-oncogene, is involved in rendering cancer
cells resistant to apoptotic stimuli [51,52]. Higher expres-
sion levels of c-met correlate with decreased rates of
remission in oropharyngeal cancer [51]. Expression levels
of c-met were downregulated in PC3 but not in MCF7 cells
treated with 5VBcl-x AS. Thus, it is possible that down-
regulation of this gene in 5VBcl-x AS treated PC3 cells helps
to activate apoptotic pathways.
Other differentially expressed genes were involved in
nucleic acid and protein synthesis. For example, RNA
polymerase II, transcription factor 4 was upregulated in
MCF7 cells but unchanged in PC3 cells. RNA polymerase II
and eukaryotic translation initiation factor, eIF2, were
upregulated in MCF7 cells but downregulated in PC3 cells
treated with 5VBcl-x AS. One interpretation of these results
is that the MCF7 cells are compensating for the insult
caused by the shift in splicing from Bcl-xL to Bcl-xS by
increasing the synthesis of new nucleic acids and proteins.
On the other hand, PC3 cells are turning off synthesis of
new nucleic acids and protein as they halt the cell cycle and
prepare to commit cell suicide.
The differentially expressed genes discussed above are
examples of how an antisense oligonucleotide can cause
changes in many genes. It will be important for the future of
antisense technology to be able to identify changes in gene
expression and identify those that are essential for produc-
ing desired antisense effects versus undesirable ones. Micro-
array technology will enable researchers to examine these
changes in gene expression on a global scale.
6. Conclusion
Although to date, there are no clinical trials with anti-
sense oligonucleotides being used to shift splicing, there are
several clinical trials in progress that examine the therapeu-
tic potential of antisense oligonucleotides to downregulate
cancer-related genes [53,54]. Preliminary results suggest
that oligonucleotides will be valuable molecular chemo-
therapeutics. Particularly interesting, however, is the use of
antisense oligonucleotides to modify splicing patterns since
it is estimated that a great majority of pre-mRNAs undergo
alternative splicing, frequently resulting in products with
antagonistic functions.
Changing the expression of a target gene is very likely to
affect the expression of other genes thereby resulting in an
altered cellular response. Examination of the gene expres-
sion profiles of antisense oligonucleotide treated cells will
provide insight to the genetic mechanisms involved in
eliciting the desired effect. Those results may be used in
many aspects of drug development, including but not
limited to the development of new combinations of chemo-
therapeutics, identification and development of safer chemo-
therapeutics, and identification of novel gene targets.
Table 2
Differentially regulated genes in PC3 and MCF7 cells after treatment with
5VBcl-x AS
Gene MCF7 PC3
Apoptosis Daxx – +
Signaling/ Met proto-oncogene 0 
proliferation/ TNFRSF8 + 
structural S100-calcium
binding protein A10
+ 0
DUSP6 + 
Dynein  0
Fibrinogen-like 1 + 0
Tubulin, beta 5 0 
Ion transport Solute carrier family 25 + 0
Solute carrier family 18 0 
Potassium
voltage-gated channel
+ 
Calcium channel,
voltage dependent beta
+ 0
Protein/nucleic Transcription factor 4 + 0
acid synthesis RNA polymerase II + 
Eukaryotic translation
initiation factor, eIF2
+ 
Gene microarray analysis uncovered several differentially regulated genes
in MCF7 and PC3 cells post 5VBcl-x AS treatment. After sorting out poor-
quality spots, the remaining cDNA spots were analyzed for differential
expression patterns. The table lists some genes that were altered greater
than 2.5-fold after 5VBcl-x AS treatment. Genes are organized in classes of
function. Upregulation of genes after treatment with 5VBcl-x AS, (+);
downregulation, (); unchanged, (0).
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